Summit Creek Advisors LLC Has $17.60 Million Holdings in Medpace Holdings, Inc. $MEDP

Summit Creek Advisors LLC cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 31.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,222 shares of the company’s stock after selling 15,879 shares during the quarter. Medpace makes up about 2.6% of Summit Creek Advisors LLC’s investment portfolio, making the stock its 8th largest position. Summit Creek Advisors LLC owned approximately 0.12% of Medpace worth $17,596,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Employees Retirement System of Texas bought a new position in shares of Medpace in the 2nd quarter worth $36,000. IFP Advisors Inc lifted its stake in shares of Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after purchasing an additional 134 shares during the last quarter. Hantz Financial Services Inc. boosted its position in Medpace by 5,075.0% during the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after purchasing an additional 203 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC boosted its position in Medpace by 514.3% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock valued at $67,000 after purchasing an additional 180 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on MEDP shares. TD Cowen increased their price target on shares of Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. Barclays raised their target price on shares of Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Truist Financial set a $555.00 price target on Medpace in a research report on Monday, October 27th. Finally, Robert W. Baird set a $613.00 price objective on Medpace in a report on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $491.27.

Medpace Trading Down 0.8%

Shares of Medpace stock opened at $595.00 on Monday. The firm’s 50 day simple moving average is $581.05 and its two-hundred day simple moving average is $502.27. The firm has a market capitalization of $16.76 billion, a price-to-earnings ratio of 41.61, a PEG ratio of 2.00 and a beta of 1.43. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the previous year, the company earned $3.01 earnings per share. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 21,503 shares of the firm’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at $8,934,900. This trade represents a 58.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 387,925 shares of company stock valued at $233,386,647. 20.30% of the stock is owned by insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.